Product Launch

SimuGen's flagship product is due for launch early 2010. This launching product will predict a wide spectrum of human liver safety concerns, a leading problem stifling drug innovation.

SimuGen is also planning to beta test its flagship liver product in Q1 2010 with a number of key industry players to further evaluate the performance of the product under market conditions.

We invite interested parties to participate in this trial to get a better understanding on the product value and to give feedback on the product features/usability, so that our product addresses all their needs.

If you are interested in a product trial please fill out the enquiry form here. We are happy to discuss this opportunity in more detail with you.

"The biopharmaceutical industry's productivity has declined over the last two decades despite a seven-fold increase in R&D spending. Many compounds are being lost in costly late-stage development and are directly linked to inadequate drug safety. Safety issues have also driven a number of highly successful drugs from the market, costing the industry billions of dollars in lost revenue and profoundly damaging public and regulatory goodwill".

Confronting Major Safety Issues of the 21^st Century - Drug Safety Executive Council